参考文献/References:
[1] Sebastian SA. Cardiovascular disease risk communication:strategies,impact,and future directions[J]. Curr Probl Cardiol,2024,49(5):102490.
[2] Henein MY,Vancheri S,Longo G,et al. The role of inflammation in cardiovascular disease[J]. Int J Mol Sci,2022,23(21):12906.
[3] Vromman A,Ruvkun V,Shvartz E,et al. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis[J]. Eur Heart J,2019,40(30):2482-2491.
[4] Hilgendorf I,Frantz S,Frangogiannis NG. Repair of the infarcted heart:cellular effectors,molecular mechanisms and therapeutic opportunities[J]. Circ Res,2024,134(12):1718-1751.
[5] Ridker PM,Macfadyen JG,Everett BM,et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab:a secondary analysis from the CANTOS randomised controlled trial[J]. Lancet,2018,391(10118):319-328.
[6] Potere N,Bonaventura A,Abbate A. Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases[J]. Arterioscler Thromb Vasc Biol,2024,44(12):2371-2395.
[7] Migliorini P,Italiani P,Pratesi F,et al. The IL-1 family cytokines and receptors in autoimmune diseases[J]. Autoimmun Rev,2020,19(9):102617.
[8] Huang J,Kuang W,Zhou Z. IL-1 signaling pathway,an important target for inflammation surrounding in myocardial infarction[J]. Inflammopharmacology,2024,32(4):2235-2252.
[9] Galozzi P,Bindoli S,Doria A,et al. The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities[J]. Autoimmun Rev,2021,20(4):102785.
[10] Abbate A,Toldo S,Marchetti C,et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease[J]. Circ Res,2020,126(9):1260-1280.
[11] Zhang Y,Liu K,Guo M,et al. Negative regulator IL-1 receptor 2 (IL-1R2) and its roles in immune regulation of autoimmune diseases[J]. Int Immunopharmacol,2024,136:112400.
[12] Supino D,Minute L,Mariancini A,et al. Negative regulation of the IL-1 system by IL-1R2 and IL-1R8:relevance in pathophysiology and disease[J]. Front Immunol,2022,13:804641.
[13] Schl?ter T,Schelmbauer C,Karram K,et al. Regulation of IL-1 signaling by the decoy receptor IL-1R2[J]. J Mol Med (Berl),2018,96(10):983-992.
[14] Pou J,Mart?nez-Gonz?lez J,Rebollo A,et al. Type ⅡI interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions[J]. Biochim Biophys Acta,2011,1811(9):556-563.
[15] Lin J,Li Q,Jin T,et al. Cardiomyocyte IL-1R2 protects heart from ischemia/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis[J]. Cell Death Dis,2022,13(1):90.
[16] Saxena A,Chen W,Su Y,et al. IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium[J]. J Immunol,2013,191(9):4838-4848.
[17] Gonz?lez L,Rivera K,Andia ME,et al. The IL-1 family and its role in atherosclerosis[J]. Int J Mol Sci,2022,24(1):17.
[18] Ajoolabady A,Pratico D,Lin L,et al. Inflammation in atherosclerosis:pathophysiology and mechanisms[J]. Cell Death Dis,2024,15(11):817.
[19] Choudhury RP,Birks JS,Mani V,et al. Arterial effects of canakinumab in patients?with atherosclerosis and type?2?diabetes or glucose intolerance[J]. J Am Coll Cardiol,2016,68(16):1769-1780.
[20] Zheng WC,Chan W,Dart A,et al. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease[J]. Eur Heart J Cardiovasc Pharmacother,2024,10(1):53-67.
[21] Orrem HL,Shetelig C,Ueland T,et al. Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction[J]. Int J Cardiol,2018,268:187-192.
[22] Simeoni E,Dudler J,Fleury S,et al. Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats[J]. Eur J Cardiothorac Surg,2007,31(2):222-228.
[23] Jiang L,Shao Y,Tian Y,et al. Nuclear alarmin cytokines in inflammation[J]. J Immunol Res,2020,2020:7206451.
[24] Zhang H,Dhalla NS. The Role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease[J]. Int J Mol Sci,2024,25(2):1082.
[25] Frangogiannis NG. Cardiac fibrosis[J]. Cardiovasc Res,2021,117(6):1450-1488.
[26] Abbate A,Wohlford GF,Del B uono MG,et al. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction:results from a pooled analysis of the VCUART clinical trials[J]. Eur Heart J Cardiovasc Pharmacother,2022,8(5):503-510.
[27] Bujak M,Dobaczewski M,Chatila K,et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling[J]. Am J Pathol,2008,173(1):57-67.
[28] Cheng CY,Baritussio A,Giordani AS,et al. Myocarditis in systemic immune-mediated diseases:Prevalence,characteristics and prognosis. A systematic review[J]. Autoimmun Rev,2022,21(4):103037.
[29] Golino M,Harding D,Delbuono MG,et al. Innate and adaptive immunity in acute myocarditis[J]. Int J Cardiol,2024,404:131901.
[30] Hua X,Hu G,Hu Q,et al. Single-cell RNA sequencing to dissect the immunological network of autoimmune myocarditis[J]. Circulation,2020,142(4):384-400.
[31] Bracamonte-Baran W,?iháková D. Cardiac autoimmunity :myocarditis[J]. Adv Exp Med Biol,2017,1003:187-221.
[32] Chang H,Wang Y,Wu W,et al. Hydrodynamics-based delivery of an interleukin-1 receptor II fusion gene ameliorates rat autoimmune myocarditis by inhibiting IL-1 and Th17 cell polarization[J]. Int J Mol Med,2013,31(4):833-840.
[33] Gorelik M,Lee Y,Abe M,et al. IL-1 receptor antagonist,anakinra,prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis[J]. Clin Exp Immunol,2019,198(1):101-110.
[34] Ammirati E,Moslehi JJ. Diagnosis and treatment of acute myocarditis:a review[J]. JAMA,2023,329(13):1098-1113.
[35] Zhang Z,Zhao L,Zhou X,et al. Role of inflammation,immunity,and oxidative stress in hypertension:new insights and potential therapeutic targets[J]. Front Immunol,2022,13:1098725.
[36] Melton E,Qiu H. Interleukin-1β in multifactorial hypertension:inflammation,vascular smooth muscle cell and extracellular matrix remodeling,and non-coding RNA regulation[J]. Int J Mol Sci,2021,22(16):8639.
[37] Krishnan SM,Sobey CG,Latz E,et al. IL-1β and IL-18:inflammatory markers or mediators of hypertension?[J]. Br J Pharmacol,2014,171(24):5589-5602.
[38] Zhao S,Zhang J,Ding F,et al. Relationships among gut microbes,the interleukin family,and hypertension:a mediation Mendelian randomization study[J]. Front Nutr,2023,10:1293170.
[39] Sharma G,Sharma AR,Bhattacharya M,et al. CRISPR-Cas9:a preclinical and clinical perspective for the treatment of human diseases[J]. Mol Ther,2021,29(2):571-586.
[40] Soroudi S,Jaafari MR,Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases:advances in genome editing and CAR T cell therapy[J]. J Control Release,2024,372:113-140.
相似文献/References:
[1]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(8):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[2]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(8):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[3]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[4]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[5]顾佳仪 刘正霞 鲁翔.白介素-1β在冠心病中的研究进展[J].心血管病学进展,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
Gu Jiayi,Liu Zhengxia,Lu Xiang.Interleukin-1 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(8):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
[6]王辉 蒋永兴 田野.下肢动脉硬化闭塞症：炎症机制与抗炎治疗的研究进展[J].心血管病学进展,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
WANG HuiJIANG YongxingTIAN Ye.Peripheral Arterial DiseaseA Research Progress Review of Inflammatory Mechanism and Anti-inflammatory Therapy[J].Advances in Cardiovascular Diseases,2020,(8):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
[7]严宁,杨春霞,马娟,等.β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J].心血管病学进展,2020,(3):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
YAN Ning,YANG Chunxia,MA Juan,et al.Effects of -sitosterolon Myocardial Ischemia-reperfusion Injury and ERK1/2 Signaling Pathway in Rats[J].Advances in Cardiovascular Diseases,2020,(8):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
[8]韩月 朱莉 宋桂仙.白介素-12家族在冠状动脉粥样硬化中的研究进展[J].心血管病学进展,2020,(5):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
HAN Yue,ZHU Li,SONG Guixian.Interleukin-12 Family in Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(8):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
[9]汪汉,刘汉雄,蔡琳.2019冠状病毒病的心血管表现[J].心血管病学进展,2020,(11):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
WANG Han,LIU Hanxiong,CAI Lin.Cardiovascular Profiles in Corona V irus Disease 2019[J].Advances in Cardiovascular Diseases,2020,(8):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[10]张颖怡 刘金波 刘欢 赵娜 赵红薇 王宏宇.全身动脉粥样硬化斑块与脑梗死的关系：北京血管病变评价研究结果[J].心血管病学进展,2021,(3):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
ZHANG YingyiLIU J inboLIU HuanZHAO NaZHAO HongweiWANG Hongyu.The Relationship Between Systematic Atherosclerotic Plaques and Cerebral Infarction:Results from Beijing Vascular Disease Evaluation Study[J].Advances in Cardiovascular Diseases,2021,(8):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]